Is Sanford Consortium For Regenerative Medicine Legit?

The Sanford Consortium For Regenerative Medicine demonstrates consistent financial operations, with annual revenues and expenses generally in the $8-9 million range over the past several years. While the organization has experienced a gradual decline in total assets from $117 million in 2014 to $84.9 million in 2023, its liabilities have also decreased, indicating a managed financial position. The consistent reporting of 0% officer compensation across all available filings suggests a strong commitment to directing resources towards its mission, or that executive compensation is structured differently (e.g., through a related entity or not directly reported as officer compensation on the 990 Part VII). This practice enhances transparency regarding direct compensation from the organization itself. The organization's spending efficiency appears stable, with expenses closely tracking revenues in most recent years, though there were periods of higher expenses relative to revenue (e.g., 2016 and 2015). The absence of reported officer compensation directly on the 990 Part VII is a notable aspect of its transparency. However, without a detailed breakdown of program, administrative, and fundraising expenses, a complete assessment of spending efficiency is challenging. The consistent filing history over 13 periods indicates good compliance and a commitment to public disclosure.